Instructions for Osteopro tablets No. 30
Composition
1 tablet contains: active ingredient: microcrystalline hydroxyapatite complex MSNAtm (MSN-Caltm) – 1000 mg (mg); excipients: fillers: microcrystalline cellulose, sodium carboxymethylcellulose, hydroxypropylcellulose; anti-caking agents: magnesium stearate, amorphous silicon dioxide. MSN-Caltm - includes 250 mg (mg) of proteins (collagen type I and non-collagen peptides, including insulin-like growth factor type I and II (IGF1 - 0.285 μg (µg), IGF2 - 0.17 μg (µg)), transforming growth factor beta (TGF-β - 0.0275 μg (µg)), osteocalcin - 604 μg (µg)) and 670 mg (mg) of calcium hydroxyapatite (including 250 mg (mg) of calcium, 125 mg (mg) of phosphorus, 4 mg (mg) of magnesium, 64 μg (µg) of zinc, 3.9 μg (µg) of iron and 1.4 μg (µg) of boron).
**typical average content of components.
GMO-free.
Properties
OSTEOPRO® contains a special compound – microcrystalline hydroxyapatite complex MSNAtm (MSN-Caltm), which is an active regulator of calcium-phosphorus metabolism. The complex contains an organic and mineral component. The mineral component (calcium hydroxyapatite) contains calcium, phosphorus and some other macro- and microelements (magnesium, zinc, iron, boron). Calcium is contained in the form of hydroxyapatite, which contributes to its more complete absorption from the gastrointestinal tract. Phosphorus contributes to the fixation of calcium in bone tissue, forming hydroxyapatite (bone mineralization phase), and also reduces its excretion by the kidneys. Magnesium is involved in the regulation of bone tissue mineralization, contributes to its flexibility, strength and improvement of reparative potential. Zinc is a cofactor of more than 300 enzymes that take part in various metabolic processes, including bone tissue. Iron is involved in the metabolism of collagen, from which bone tissue trabeculae are built, including. Boron has a pronounced effect on the growth processes of bone tissue and cartilage cells, increasing the level of osteogenesis proteins - osteocalcin, type 1 collagen, bone morphogenesis proteins 4, 6 and 7, as well as osteopontin, bone sialoprotein (BSP gene), Runx2 protein. The organic component is represented by proteins and peptides (growth factors, osteocalcin, collagen, etc.). Among the growth factors, the most important are: insulin-like growth factors 1 and 2 (IGF1, IGF2), transforming growth factor beta (TGF-β). IGF1 and IGF2 are able to influence the synthesis of collagen and other bone proteins, as well as activate the proliferation and maturation of osteoblasts. There is data on their effect on the formation of cartilage tissue and fracture healing in the experiment. TGF-β has a significant effect on bone metabolism, in particular the proliferation of the cell pool and the main substance of bone tissue. One of the key growth factors that takes an active part in all phases of the reparative process in a fracture.
Recommendations for use
OSTEOPRO® is an additional source of calcium, phosphorus and proteins (collagen, growth factors, osteocalcin). It is recommended for the regulation of calcium-phosphorus metabolism in case of calcium deficiency in the body, osteoporosis and to improve bone growth in case of fractures.
Method of application
For fractures: from the first day of the fracture and for 14 days, it is recommended to take 1 tablet per day, washed down with a small amount of drinking water, preferably during meals. From the 15th day, it is recommended to switch to taking 2 tablets per day (in 2 doses), washed down with a small amount of drinking water, preferably during meals. To make swallowing easier, the tablet can be chewed. On the recommendation of a doctor, the recommended daily dose may be increased. The course of use is determined by the doctor individually. The minimum recommended course of use is 1 month. Before use, it is recommended to consult a doctor.
In other conditions for the purpose of regulating calcium-phosphorus metabolism, with calcium deficiency in the body, osteoporosis: adults should take 2-4 tablets per day (in 2 doses), washed down with a small amount of drinking water, preferably during meals. To facilitate swallowing, the tablets can be chewed. On the recommendation of a doctor, the recommended daily dose may be increased. The course of use is determined by the doctor individually. The minimum recommended course of use is 1 month. Before use, it is recommended to consult a doctor.
Reservation
Do not exceed the recommended daily dose. OSTEOPRO® should not be used as a substitute for a balanced diet.
Contraindication
Individual sensitivity to any of the components, hypercalcemia, hypercalciuria, urolithiasis, tissue calcification, severe renal dysfunction, hyperproliferative processes.
Release form
Tablets weighing 1.5 g ± 7.5%, 10, 14, 30, or 60 tablets in a jar packed in a cardboard box.
Expiration date
24 months from the date of manufacture.
Storage conditions
Store in the original packaging at a temperature of 4°C to 25°C in a dry place, protected from light and out of the reach of children.
Producer
Developer of MCHA™ (MCH-Cal™) manufacturing technology and supplier of active ingredients: Waitaki Biosciences a division of PharmaZen Limited, 320 Port Hills Rd, Hillsborough 8022, Christchurch, New Zealand.
